Puberty blockers do not improve the mental health of children and young adults with gender dysphoria, according to a study

(ZENIT News / Washington, 08.29.2026).- A federally USA funded study of young people receiving puberty blockers and hormone treatments has produced a finding that is unlikely to satisfy either side of the increasingly polarized debate over medical interventions for minors: after two years, the participants’ mental-health measures did not show a clinically significant improvement, although neither did they show an overall deterioration.

The final report, “The Impact of Early Medical Treatment in Transgender Youth,” was obtained by the Oversight Project and reported by the Daily Signal after months of controversy surrounding its publication. The National Institutes of Health had initially awarded a nine-year grant of up to $10 million through Children’s Hospital Los Angeles for the research, which was led by Dr. Johanna Olson-Kennedy, a physician specializing in gender-affirming care.

The study involved participants as young as 8. Those receiving puberty blockers included adolescents up to 16, while the hormone-treatment group included participants up to age 20. It is important, however, to understand what the study can and cannot establish: it was observational, meaning the NIH funding did not itself cause the medical interventions to be administered.

According to the final report, mental-health measures remained relatively stable over the two-year period. The researchers reported no worsening in mental or emotional health, while suicidal ideation declined from baseline to 24 months. Average scores on mental-health assessments remained within a range the researchers considered clinically insignificant over the period studied. The report also noted higher life-satisfaction scores and reductions in depression and anxiety.

That combination of findings deserves more careful attention than either triumphalist or catastrophic interpretations allow.

The study does not demonstrate that gender-related medical treatment produces no benefit whatsoever. Nor does it provide evidence that the interventions caused a general deterioration in mental health. What it does challenge is a much stronger claim: that medical transition during adolescence can straightforwardly be presented as a treatment that produces substantial improvements in young people’s mental health.

That distinction is particularly important because the mental-health argument has played a central role in the public debate. Advocates of medical transition for minors have long argued that denying such treatment could expose vulnerable young people to depression, psychological distress and suicide. Yet at the beginning of this study, the participants were already a highly vulnerable population: approximately half had clinically concerning levels of depression or anxiety, around two-thirds reported suicidal thoughts, and nearly one quarter reported having attempted suicide.

Those baseline figures also illustrate why interpreting the subsequent results is inherently complicated. These were not psychologically typical children randomly assigned to receive or not receive treatment. They entered the study with substantial levels of distress, making it difficult to determine from an observational design precisely which factors accounted for subsequent changes.

The publication itself became part of the controversy. The study involved nearly 100 young people, but reporting in late 2024 indicated that its results were not initially going to be published because Olson-Kennedy had expressed concern that the findings could be used for political purposes.

That history makes transparency particularly important. When public money is used to investigate interventions involving children, the public has a legitimate interest in seeing the complete evidence, including findings that complicate prevailing narratives. Scientific results should not be withheld because they might be inconvenient to one side of a political argument.

The report also raises questions beyond mental health. Researchers identified possible effects involving bone density, reproductive health and height, adding to the areas that require careful long-term investigation.

Those questions become more consequential when the patients are children. Puberty is not simply an unwanted physical process that can be paused without broader biological consequences; it is a developmental stage involving sexual maturation, bone development, growth and reproductive capacity. That does not by itself determine what medical decision is appropriate for any particular patient, but it does explain why the threshold for evidence should be high when interventions are begun at very young ages.

The report’s treatment of mortality also deserves scrutiny. The researchers noted that their retention calculations excluded participants who withdrew consent, died or had not completed their extended follow-up. Critics have pointed to an earlier publication involving two participants who died by suicide and argued that the circumstances surrounding those deaths should be made clearer. The material available here does not establish the causes of death, and it would therefore be inappropriate to attribute them to either the treatment or the underlying condition without further evidence.

This is precisely why the controversy should ultimately be resolved by better evidence rather than competing political narratives.

The interests at stake are unusually serious. Children experiencing gender dysphoria deserve compassion, psychological support and protection from humiliation or discrimination. At the same time, compassion does not require lowering the evidentiary standard for medical interventions that can affect a child’s developing body and future reproductive life. A child is not a political symbol, and neither advocates nor opponents of gender medicine should treat vulnerable minors as instruments in an ideological struggle.

The study therefore leaves an important question open rather than closing the debate. If the principal justification for early medical intervention is that it substantially improves mental health, the available findings in this study do not provide a dramatic confirmation of that proposition. If the alternative claim is that treatment necessarily harms young people, the report does not establish that either.

What it does provide is a reason for greater honesty about uncertainty.

For parents, physicians and policymakers, that may be the most consequential lesson of all. The appropriate response to imperfect evidence concerning children should not be ideological certainty, but rigorous follow-up, full disclosure of results and a willingness to distinguish what is known from what remains unproven.

After years of political argument, the publication of the study offers something more valuable than another slogan: an opportunity to ask harder questions about how medicine should respond when vulnerable children, irreversible decisions and incomplete evidence meet.

Thank you for reading our content. If you would like to receive ZENIT’s daily e-mail news, you can subscribe for free through this link.